Breast Cancer Prevention Study: Are Healthy Women Put at Risk by Federally Funded Research? : Hearing Before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, Second Session, October 22, 1992U.S. Government Printing Office, 1994 - 272 páginas |
Otras ediciones - Ver todas
Términos y frases comunes
adjuvant adjuvant tamoxifen BCPT blood clots bone fractures Breast Cancer Action breast cancer prevention Cancer Prevention Trial Cancer Research centers chemoprevention clinical trials concern cyclophosphamide developing breast cancer Director disease dose Drug Administration effects of tamoxifen eligible endometrial cancer estrogen exam Food and Drug Fugh-Berman GREENWALD Gregory Burke healthy women high risk hormone human increased risk informed consent informed consent form Lancet liver cancer menopausal National Cancer Institute National Surgical Adjuvant NSABP P-1 ocular toxicity Oncology osteoporosis participants patients PAYNE percent physician placebo postmenopausal postmenopausal women potential premenopausal women prevent breast cancer prevention of breast prevention study Public Health rats receiving tamoxifen reduce reported risk factors risk of breast risk of developing risks and benefits side effects Subcommittee Surgical Adjuvant Breast taking tamoxifen tamoxifen study tamoxifen therapy tamoxifen treatment tamoxifen trial tests uterine cancer vaginal woman women with breast Women's Health
Pasajes populares
Página 252 - Bartels. the administrative director of the Center for Biomedical Ethics at the University of Minnesota, outlined some of the concerns raised at an NIH/ELSI conference on genetic counseling in the United States.
Página 37 - Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.
Página 100 - My colleagues and I will be pleased to respond to your questions. [The prepared statement of Dr.
Página 5 - Committee, all witnesses before the committee will be sworn in. From time to time during the hearing, we will be inserting into the record, without objection, documents relevant to this matter. Before we begin, let me say to all of our witnesses that the full text of your written statements will be inserted in the hearing record.
Página 101 - Department of Health and Human Services before the Subcommittee on Human Resources and Intergovernmental Relations House Committee on Government Operations Representative Edolphus Towns, Chairman October 15, 1993 Statement of Dr.
Página 188 - NIH: the National Cancer Institute (NCI); the National Heart, Lung, and Blood Institute (NHLBI); the National Institute of Dental Research (NIDR); the National Institute of Diabetes and Digestive and Kidney Diseases...
Página 5 - Operations, all witnesses before the committee will be sworn in. From time to time during the hearing we will be inserting into the record, without objection, documents relevant to this matter. Before we begin, let me say to all of our witnesses that the full text of your written statements will be inserted into the hearing record.
Página 75 - A clinical trial to determine the worth of tamoxifen for preventing breast cancer.
Página 47 - American Public Health Association 1015 15th Street NW Washington, DC 20005 (202) 789-5600...
Página 1 - Washington, DC. The subcommittee met, pursuant to notice, at 10:07 am, in room 2154, Rayburn House Office Building, Hon.